Montelukast Synthon (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 and related mediators from binding. This inhibition reduces bronchoconstriction, mucus production, and inflammation in the respiratory tract, helping to control asthma and allergy symptoms.

The appropriate dose is determined by the prescribing clinician based on the patient’s age, condition, and response to therapy. Dosage forms and strengths are selected to match the individual treatment plan.

Safety data are limited. Women who are pregnant or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting Montelukast Synthon.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting bronchodilators. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control beyond inhaled therapy.

Store Montelukast Synthon at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

Montelukast is taken orally, usually as a tablet or chewable form, once daily in the evening. It should be swallowed whole with water unless a specific formulation advises otherwise.

Serious risks include severe allergic reactions such as angioedema, rare skin conditions like Stevens‑Johnson syndrome, and neuropsychiatric events including mood changes, depression, or suicidal thoughts. Any of these symptoms require immediate medical attention.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe liver impairment, and it should be avoided in those taking medications that have major interactions without professional supervision.